Conference Coverage
Media
NewsNetwork
OncLive® TV
Peer Exchange
Insights
Podcasts
Rapid Readouts
Attend An Event
State of the Science Summit
Regional Seminar Series
PER Conferences
Giants of Cancer Care
ISGIO
Webinars
OncLive Community

Register for a live broadcast to learn more about TRODELVY (sacituzumab govitecan-hziy) with Dr. Hope S. Rugo

SPECIALTY TOPICS
CURRENTLY VIEWING
All Specialties
Breast Cancer
Multiple Myeloma
Lung Cancer
Immuno-Oncology News
Gynecologic Oncology
Gastrointestinal Cancer
Colorectal Cancer
Ovarian Cancer
Prostate Cancer
Precision Medicine in Oncology®
Neoadjuvant HER2+
More >>
<< View More Conferences

2019 Lynn Sage Breast Cancer Symposium

Oncology Conference Multimedia
View more videos >>
Dr. Osborne on Evaluating HER2 Positivity in Breast Cancer
Dr. Osborne on Evaluating HER2 Positivity in Breast Cancer
Dr. Barrio on Neoadjuvant Chemo to De-Escalate Axillary Node Dissection in Breast Cancer
Dr. Barrio on Neoadjuvant Chemo to De-Escalate Axillary Node Dissection in Breast Cancer
Dr. Morrow on Patient Selection for Nipple Sparing Mastectomy
Dr. Morrow on Patient Selection for Nipple Sparing Mastectomy
Oncology Conference Articles
Immunotherapy for Breast Cancer: What's New and What's on the Horizon?
Immunotherapy for Breast Cancer: What's New and What's on the Horizon?
Immunotherapy may finally be taking center stage in breast cancer, although much work remains to be done.
Earlier Diagnosis and Treatment Are Next Steps in TNBC Paradigm
Earlier Diagnosis and Treatment Are Next Steps in TNBC Paradigm
There is an unprecedented array of therapeutic options for patients with triple-negative breast cancer, with more approaches on the horizon.
Rugo Highlights Latest Advances in TNBC Treatment
Rugo Highlights Latest Advances in TNBC Treatment
Hope S. Rugo, MD, discusses the latest advancements in the treatment landscape for patients with TNBC and highlights some data from clinical trials presented at the 2019 ESMO Congress.
Use of Neoadjuvant Endocrine Therapy Showcases Testing Capabilities in Breast Cancer
Use of Neoadjuvant Endocrine Therapy Showcases Testing Capabilities in Breast Cancer
In breast cancer, neoadjuvant endocrine therapy shows promise in a variety of areas, including as an excellent testing platform, Ingrid A. Mayer, MD, MSCI, said in a presentation during the 2019 Lynn Sage Breast Cancer Symposium.
Trends in Pathologic Complete Response After Neoadjuvant Chemo in Breast Cancer
Trends in Pathologic Complete Response After Neoadjuvant Chemo in Breast Cancer
In contemporary breast cancer clinical practice, the correlation between achieving a pathologic complete response after neoadjuvant chemotherapy and significantly improved outcomes after chemotherapy has been well established. However, in a discussion at the 2019 Lynn Sage Breast Cancer Symposium, William J. Gradishar, MD, cautioned colleagues that there is more to the story when one looks at long-term data in these patients.
Inflammatory Breast Cancer Has Diagnostic Challenges, Requires More Awareness
Inflammatory Breast Cancer Has Diagnostic Challenges, Requires More Awareness
Naoto Tada Ueno, MD, PhD, FACP, discusses the diagnosis and treatment of patients with inflammatory breast cancer and highlights the biggest challenges in both diagnosing and treating this patient population.
Patient Selection Key When De-Escalating Radiation in Breast Cancer
Patient Selection Key When De-Escalating Radiation in Breast Cancer
Jonathan B. Strauss, MD, MBA, discussed the role of hypofractionated radiotherapy in patients with breast cancer and offered advice on treatment selection.
Multipronged De-Escalated Chemo Strategy Could Yield Best Results in HER2+ Breast Cancer
Multipronged De-Escalated Chemo Strategy Could Yield Best Results in HER2+ Breast Cancer
As more becomes known about the biology of HER2-positive early breast cancer, C. Kent Osborne, MD, says that a multipronged strategy is the best approach regarding de-escalating chemotherapy in this patient population.
Updated HER2+ Breast Cancer Guidelines Offer Additional Insight, But Questions Remain
Updated HER2+ Breast Cancer Guidelines Offer Additional Insight, But Questions Remain
Clinical guidelines have been necessary to help oncologists stay current in the face of rapidly evolving knowledge in HER2-positive breast cancer.
Publication Bottom Border
Border Publication
 
x